Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Issue 7 (7th June 2022) - Barr, Paul M.; Smith, Stephen D.; Roschewski, Mark J.; O'Brien, Susan M.; Sharman, Jeff P.; Melear, Jason M.; Patel, Priti; Calvo, Roser; Yang, Helen; Spurgeon, Stephen E.